专利检索 ap:("SHANGHAI INST MATERIA MEDICA CAS") AND inv:"CHEN YI" 第 1 页

1.

发明公开
2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 审中-公开

公开(公告)号：EP3225619A4

公开(公告)日：2018-05-23

申请号：EP15863532

申请日：2015-11-18

申请人： SHANGHAI INST MATERIA MEDICA CAS , GUANGZHOU INST BIOMED & HEALTH

发明人： DING KE , DING JIAN , CHAN SHINGPAN , GENG MEIYU , REN XIAOMEI , XIE HUA , TU ZHENGCHAO , CHEN YI

IPC分类号： C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , A61P35/00 , A61P35/02 , C07D239/47 , C07D401/02 , C07D403/12

CPC分类号： C07D403/12 , A61K31/4523 , A61K31/505 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/551 , C07D239/47 , C07D239/48 , C07D401/02 , C07D401/12

摘要： Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.

2.

发明公开
SULFATED POLYGULONIC ACID POLYSACCHARIDE OR PHARMACEUTICAL SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF 有权
标题翻译：硫酸化多糖POLYGULONSÄURE或其药用盐，方法以及这种生产的使用

公开(公告)号：EP3018147A4

公开(公告)日：2017-04-05

申请号：EP14819337

申请日：2014-07-02

申请人： SHANGHAI INST MATERIA MEDICA CAS

发明人： DING JIAN , AI JING , CHEN YI , HUANG XUN

IPC分类号： C08B37/04 , A61K31/734 , A61K31/737 , A61P35/00 , A61P35/04

CPC分类号： A61K31/737 , C08B37/0084 , C08L5/00

摘要： A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerising factor activity inhibitors and actin-aggregation inhibitors.